Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.
Jing-Jing WuWen-Hua WangMeng DongShan-Shan MaXu-Dong ZhangLi-Nan ZhuSong-Tao NiuMeng-Jie DingJie-Ming ZhangLei ZhangXin LiLing LiZhen-Chang SunXin-Hua WangXiao-Rui FuZhao-Ming LiYu ChangFei-Fei NanJia-Qin YanHui YuXiao-Long WuZhi-Yuan ZhouMing-Zhi ZhangPublished in: Investigational new drugs (2022)
Orelabrutinib-based regimens were efficacious and well-tolerated in patients with CNSL. These combined therapies offer a new potential therapeutic strategy for patients with CNSL.